Seroatlas · Human Serome Atlas

LILRA3

Leukocyte immunoglobulin-like receptor subfamily A member 3

Also known as: LIRA3_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N6C8
Gene: LILRA3
Canonical length: 439 aa

OverviewNCBI Gene

No narrative summary is available for LILRA3 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

439 residues, UniProt reviewed canonical sequence.

>Q8N6C8|LILRA3
     1  MTPILTVLIC LGLSLDPRTH VQAGPLPKPT LWAEPGSVIT QGSPVTLRCQ GSLETQEYHL
    61  YREKKTALWI TRIPQELVKK GQFPILSITW EHAGRYCCIY GSHTAGLSES SDPLELVVTG
   121  AYSKPTLSAL PSPVVTSGGN VTIQCDSQVA FDGFILCKEG EDEHPQCLNS HSHARGSSRA
   181  IFSVGPVSPS RRWSYRCYGY DSRAPYVWSL PSDLLGLLVP GVSKKPSLSV QPGPVVAPGE
   241  KLTFQCGSDA GYDRFVLYKE WGRDFLQRPG RQPQAGLSQA NFTLGPVSRS YGGQYTCSGA
   301  YNLSSEWSAP SDPLDILITG QIRARPFLSV RPGPTVASGE NVTLLCQSQG GMHTFLLTKE
   361  GAADSPLRLK SKRQSHKYQA EFPMSPVTSA HAGTYRCYGS LSSNPYLLTH PSDPLELVVS
   421  GAAETLSPPQ NKSDSKAGE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LILRA3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.03
gnomAD pLI: 0
gnomAD missense Z: -0.88

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

inhibitory MHC class I receptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LILRA3 as an antibody target. Whether an autoantibody or antibody against LILRA3 could matter depends on whether native LILRA3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LILRA3 is annotated as secreted, so native LILRA3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LILRA3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...